As the first and only market research firm to specialize in the stem cell industry, BioInformant has released the “Global Induced Pluripotent Stem Cell (iPSC) Industry Report – Market Size, Trends, and Forecasts, 2023.” This global strategic report provides breaking coverage of the global iPSC market, including market size figures with future forecasts through 2030. [Read more…]
The Pipeline for iPSC-Derived Cell Therapeutics in 2023
Despite progress involving the use of induced pluripotent stem cells (iPSCs) within disease modeling and drug discovery applications, it will be a long path to achieve the broad-scale use of iPSC-derived cell types in human patients. [Read more…]
Takara Bio Establishes Foothold in the Pluripotent Stem Cell Market
A few years back, Takara Bio 
announced that the Medical Products Agency (“MPA”), the Swedish national authority responsible for regulation of drug and medical products, had granted the company a manufacturing license for derivation and banking of human embryonic stem (hES) cells to be produced under GMP conditions. The cells were to be produced at Takara Bio’s manufacturing laboratory located in Göteborg, Sweden, within Takara Bio Europe’s facility.
This announcement made Takara Bio the first company worldwide to offer this service for human ESCs.
Takara Bio’s Role with Human Pluripotent Stem Cells
The significance of this event is that Takara Bio is capable of providing a predictable and reliable source of hES cells for future cellular therapeutic development by sourcing starting material from FDA-compliant facilities, according to FDA guidelines and leveraging its proprietary, feeder-free hES cell establishment method, which is animal- and human-component free. [Read more…]
Development of iPSC-derived Disease Models
Human induced pluripotent stem cell (iPSC)-based models are a valuable resource for studying disease mechanisms in vitro at the cellular level[1], screening potential new therapeutics[2], and investigating the propensity and mechanism for the development of toxic side effects caused by a drug treatment[3]. Such iPSC-based models enable research to be performed under defined experimental conditions and in a reproducible manner. [Read more…]
Induced Pluripotent Stem Cell (iPS Cell) Applications in 2023
Since the discovery of induced pluripotent stem cells (iPSCs) in 2006, a large and thriving research products market has emerged, largely because the cells are non-controversial and can be generated directly from adult cells. It is clear that iPSCs represent a lucrative market segment, because methods for commercializing this cell type are expanding every year and clinical studies investigating iPSCs are swelling in number. [Read more…]
- 1
- 2
- 3
- …
- 8
- Next Page »
